Vasopressin for the treatment of vasodilatory shock: an ESICM systematic review and a meta-analysis
© Polito et al. 2011
Published: 1 March 2011
We examine benefits and risks of vasopressin/terlipressin use in patients with vasodilatory shock on mortality and morbidity.
We searched the CENTRAL, MEDLINE, Embase, and LILACS (through to August 2010) databases. Randomized and quasi-randomized trials of vasopressin/terlipressin versus placebo or supportive treatment in adult and pediatric patients with vasodilatory shock were included. The primary outcome for this review was short-term all-cause mortality.
No significant effect of vasopressin/terlipressin therapy on all-cause mortality was demonstrated. Overall, there is no evidence to support the routine use of vasopressin or terlipressin in the management of patients with vasodilatory shock. There was, however, a reduction in the dose of norepinephrine used for those patients receiving vasopressin/terlipressin.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.